Compounds > carbovir triphosphate
Page last updated: 2024-10-15

carbovir triphosphate

Description

carbovir triphosphate: metabolite of abacavir [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

carbovir triphosphate : The organic triphosphate that is the 5'-triphosphate of (-)-carbovir. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135499583
CHEMBL ID1201395
CHEBI ID64174
SCHEMBL ID23391359
MeSH IDM0183605

Synonyms (26)

Synonym
carbovir triphosphate
(+/-)-cis-2-amino-1,9-dihydro-9-[4-oxymethyltriphosphate-2-cyclopenten-1-yl-]purine-6-one
[[(1s,4r)-4-(2-amino-6-oxo-1h-purin-9-yl)cyclopent-2-en-1-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
triphosphoric acid, p-[[4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl]methyl] ester, cis-(1)-
carbovir-tp
triphosphoric acid, p-[[4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl]methyl] ester (1s-cis)-
(-)-carbovir triphosphate
140850-29-9
(-)-cbv-tp
chebi:64174 ,
CHEMBL1201395
carbovir 5'-triphosphate, (-)-
triphosphoric acid, p-((4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl)methyl) ester (1s-cis)-
unii-546k56p9dl
546k56p9dl ,
(1s-cis)-triphosphoric acid, p-((4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl)methyl) ester
[(1s,4r)-4-(2-amino-6-oxo-1,6-dihydro-9h-purin-9-yl)cyclopent-2-en-1-yl]methyl tetrahydrogen triphosphate
129941-14-6
(-)-carbovir 5'-triphosphate
carbovir 5'-triphosphate
triphosphoric acid, p-(((1s,4r)-4-(2-amino-1,6-dihydro-6-oxo-9h-purin-9-yl)-2-cyclopenten-1-yl)methyl) ester
DTXSID50156268
Q27133096
SCHEMBL23391359
HY-131607
CS-0137554

Pharmacokinetics

ExcerptReference
" Pharmacokinetic parameters were calculated using noncompartmental methods."( Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Boffito, M; Fletcher, C; Guerini, EM; Hay, PE; Higgs, C; Lou, Y; Min, SS; Moyle, G; Song, IH; Yuen, GJ, 2009)
"HIV-infected subjects on abacavir (600 mg once daily) underwent steady-state pharmacokinetic assessments without and with darunavir/ritonavir or raltegravir."( Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Abongomera, G; Back, D; Boffito, M; Dickinson, L; Gazzard, B; Gedela, K; Jackson, A; Khoo, S; Moyle, G; Taylor, J, 2012)

Dosage Studied

ExcerptReference
" In 27 evaluable subjects, the regimens provided bioequivalent ABC daily areas under the concentration-time curve from 0 to 24 h (AUC(0-24)) and comparable CBV-TP concentrations at the end of the dosing interval (C(tau))."( Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Boffito, M; Fletcher, C; Guerini, EM; Hay, PE; Higgs, C; Lou, Y; Min, SS; Moyle, G; Song, IH; Yuen, GJ, 2009)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic triphosphateAn organic phosphate ester formed by condensation of triphosphoric acid with one or more alcohols.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (11)

PathwayProteinsCompounds
Abacavir ADME624
Abacavir metabolism423
Disease1278231
Infectious disease89579
HIV Infection20112
HIV Life Cycle13010
Early Phase of HIV Life Cycle182
Reverse Transcription of HIV RNA62
Minus-strand DNA synthesis62
Drug ADME6387
Viral Infection Pathways72739

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)1.14500.00011.076810.0000AID323427; AID323429; AID323441; AID323443
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd4.00000.00062.40599.8000AID572771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID323420Inhibition of HIV1 reverse transcriptase 41L/67N/70R/184V/210W/215Y mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555776Drug level at end of dosing interval in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555789Weight normalized Cmax in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323418Inhibition of HIV1 reverse transcriptase 184V mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555773Drug level at end of dosing interval in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555980Weight normalized Drug level at end of dosing interval in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID572772Ratio of Kpol to Kd for HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID323438Inhibition of HIV1 reverse transcriptase 75I/77L/116Y/151M/184V mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555973Cmax in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323432Inhibition of HIV1 reverse transcriptase 184V mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID572771Binding affinity to HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID323434Inhibition of HIV1 reverse transcriptase 41L/67N/70R/184V/210W/215Y mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555767Weight normalized Drug level at end of dosing interval in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323417Inhibition of HIV1 reverse transcriptase wild type HXB2(a) in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID572765Selectivity, ratio of Kpol to Kd for dGTP to Kpol to Kd for compound at HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID555762Ratio of Drug level at the end of dosing interval in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to Drug level at the end of dosing interval in HIV infected patient carbovir-triphosphate level per million cells at 300 m2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323421Inhibition of HIV1 reverse transcriptase 41L/69S-SG/210W/215Y mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555978Weight normalized AUC (0 to 24 hrs) in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555782AUC (0 to 24 hrs) in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555972AUC (0 to 24 hrs) in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555777AUC (0 to 24 hrs) in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323419Inhibition of HIV1 reverse transcriptase 41L/67N/70R/210W/215Y mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555793Weight normalized Drug level at end of dosing interval in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID422881Antiviral activity against HIV1 LAI with reverse transcriptase K70E mutation relative to wild type HIV1 LAI2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
AID555790Weight normalized Drug level at end of dosing interval in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555764Ratio of AUC in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to AUC in HIV infected patient carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555778Cmax in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555760Ratio of weight normalized Cmax in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to weight normalized Cmax in HIV infected patient carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555784Drug level at end of dosing interval in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555771Weight normalized Cmax in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323439Inhibition of HIV1 reverse transcriptase wild type HXB2(b) by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323424Inhibition of HIV1 reverse transcriptase 75I/77L/116Y/151M/184V mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555763Ratio of Cmax in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to Cmax in HIV infected patient carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555979Weight normalized Cmax in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555792Weight normalized Cmax in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555761Ratio of weight normalized AUC in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to weight normalized AUC in HIV infected patient carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323428Inhibition of HIV1 LAI reverse transcriptase 65R mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555785AUC (0 to 24 hrs) in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323422Inhibition of HIV1 reverse transcriptase 41L/69S-SG/184V/210W/215Y mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555775AUC (0 to 24 hrs) in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323433Inhibition of HIV1 reverse transcriptase 41L/67N/70R/210W/215Y mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323426Inhibition of HIV1 LAI reverse transcriptase 41L/67N/70R/215Y/219Q mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555794AUC (0 to 24 hrs) in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323442Inhibition of HIV1 LAI reverse transcriptase 65R mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555976Weight normalized Cmax in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID556008Ratio of AUC in HIV infected male patient assessed as carbovir-triphosphate level per million cells to AUC in HIV infected male patient at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323427Inhibition of HIV1 LAI reverse transcriptase wild type in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID572770Activity at HIV1 reverse transcriptase measured after 30 mins2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID555772Weight normalized AUC (0 to 24 hrs) in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323431Inhibition of HIV1 reverse transcriptase wild type HXB2(a) by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555783Cmax in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555788Weight normalized AUC (0 to 24 hrs) in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555975Weight normalized AUC (0 to 24 hrs) in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555759Ratio of weight normalized Drug level at the end of dosing interval in HIV infected patient carbovir-triphosphate level per million cells at 600 mg QD to weight normalized Drug level at the end of dosing interval in HIV infected patient carbovir-triphosph2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323425Inhibition of HIV1 reverse transcriptase wild type HXB2(b) in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555971Drug level at end of dosing interval in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555786Cmax in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555974Drug level at end of dosing interval in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323430Inhibition of HIV1 pNL4-3 reverse transcriptase 115F mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555970Cmax in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323435Inhibition of HIV1 reverse transcriptase 41L/69S-SG/210W/215Y mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323423Inhibition of HIV1 reverse transcriptase 75I/77L/116Y/151M mutant in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323443Inhibition of HIV1 pNL4-3 reverse transcriptase wild type pNL4-3 by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555769Weight normalized AUC (0 to 24 hrs) in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555787Drug level at end of dosing interval in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323440Inhibition of HIV1 LAI reverse transcriptase 41L/67N/70R/215Y/219Q mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323441Inhibition of HIV1 LAI reverse transcriptase wild type LAI by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323436Inhibition of HIV1 reverse transcriptase 41L/69S-SG/184V/210W/215Y mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID323429Inhibition of HIV1 pNL4-3 reverse transcriptase wild type pNL4-3 in presence of 5 mM ATP by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555977Weight normalized Drug level at end of dosing interval in HIV infected female patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555791Weight normalized AUC (0 to 24 hrs) in HIV infected male patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323437Inhibition of HIV1 reverse transcriptase 75I/77L/116Y/151M mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555774Cmax in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID323444Inhibition of HIV1 pNL4-3 reverse transcriptase 115F mutant by heteropolymeric DNA polymerase assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.
AID555770Weight normalized Drug level at end of dosing interval in HIV infected patient assessed as carbovir-triphosphate level per million cells at 300 mg BID by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
AID555768Weight normalized Cmax in HIV infected patient assessed as carbovir-triphosphate level per million cells at 600 mg QD by HPLC/MS/MS analysis2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (10.53)18.2507
2000's13 (68.42)29.6817
2010's4 (21.05)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		5.05316-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		2.0110aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
cytidine triphosphate
Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.		2.4220cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.0110L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
2'-deoxyadenosine triphosphate
2'-deoxyadenosine triphosphate: RN given refers to unlabeled parent cpd		2.05102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		2.9440dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		2.4320pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.9240azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
lamivudine
[no description available]		3.1250monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
emtricitabine
Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.		2.4420monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
thymidine 5'-triphosphate
thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.		2.4120pyrimidine 2'-deoxyribonucleoside 5'-triphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite
2',3'-dideoxythymidine triphosphate
ddTTP : A pyrimidine 2',3'-dideoxyribonucleoside 5'-triphosphate having thymine as the nucleobase.		1.9710pyrimidine 2',3'-dideoxyribonucleoside 5'-triphosphate;
thymidine phosphate
2'-deoxycytidine 5'-triphosphate
2'-deoxycytidine 5'-triphosphate: RN given refers to unlabeled parent cpd		2.05102'-deoxycytidine phosphate;
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite
2',3'-dideoxyadenosine triphosphate
[no description available]		2.0510purine deoxyribonucleoside triphosphate
stavudine triphosphate
stavudine triphosphate: shows termination substrate properties in DNA synthesis catalyzed by several different DNA polymerases; also abbreviated d4TTP		2.0510
zidovudine triphosphate
[no description available]		2.9240
2',3'-dideoxycytidine 5'-triphosphate
2',3'-dideoxycytidine 5'-triphosphate: inhibits vesicular stomatitis virus RNA synthesis		2.0510
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		5.0531divalent inorganic anion;
phosphite ion
darunavir
Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.		8.4611carbamate ester;
furofuran;
sulfonamide		antiviral drug;
HIV protease inhibitor
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		8.46111,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
abacavir
abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.		7.771142,6-diaminopurinesantiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor
mycophenolic acid
Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.		2.01102-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
3'-azido-2',3'-dideoxyadenosine
[no description available]		2.0510
lamivudine triphosphate
[no description available]		7.9440
tenofovir
tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.		10.2741nucleoside analogue;
phosphonic acids		antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor
tenofovir diphosphate
[no description available]		2.0510
tenofovir disoproxil fumarate
tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.		2.0510fumarate saltantiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug
raltegravir potassium
Raltegravir Potassium: A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.		3.4611
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		2.08103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
2'-deoxyguanosine 5'-phosphate
2'-deoxyguanosine 5'-phosphate: RN given refers to parent cpd.. 2'-deoxyguanosine 5'-monophosphate : A purine 2'-deoxyribonucleoside 5'-monophosphate having guanine as the nucleobase.		2.0110deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-monophosphate		Escherichia coli metabolite;
mouse metabolite
deoxyguanosine triphosphate
[no description available]		5.4151deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		2.4420purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
nsc 614846
carbovir: structure given in first source; potent & selective anti-HIV agent. carbovir : Cyclopent-2-en-1-ylmethanol in which the 4-position is substituted by a 2-amino-6-hydroxy-9H-purin-9-yl group such that the two substitutents on the cyclopentene ring are in a cis relationship. The (-)-enantiomer, also known as carbovir, is a potent inhibitor of HIV replication replication in cell cultures.. (-)-carbovir : The (active) (-)-enantiomer of the carbocyclic analogue of 2',3'-dideoxy-2',3'-didehydroguanosine.		2.4120carbovirHIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyguanosine
[no description available]		2.0510
2',3'-dideoxyguanosine 5'-triphosphate
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		07.694
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		07.694
Acquired Immune Deficiency Syndrome
[description not available]		02.0110
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		02.0110
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		01.9810